Mark R Middleton - JoVE Visualize

Showing results (31-40 of 136) with videos related to

Pageof 14

Sort By:

Journal for Immunotherapy of Cancer|June 8, 2019

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanomaRobert H I Andtbacka, Frances Collichio, Kevin J Harrington, et al.

British Journal of Cancer|June 2, 2025

Preferences for multi-cancer tests (MCTs) in primary care: discrete choice experiments of general practitioners and the general public in EnglandJohn Buckell, Nomalanga Madyiwa, Gail Hayward, et al.

International Journal of Cancer|February 6, 2019

Immunophenotypes of pancreatic ductal adenocarcinoma: Meta-analysis of transcriptional subtypesInes de Santiago, Christopher Yau, Lara Heij, et al.

Frontline Gastroenterology|October 29, 2019

Immunotherapy-related hepatitis: real-world experience from a tertiary centreVincent Cheung, Tarun Gupta, Miranda Payne, et al.

Ultrasound in Medicine & Biology|June 29, 2004

Contrast-enhanced ultrasound assessment of tissue response to high-intensity focused ultrasoundJames E Kennedy, Gail R ter Haar, Feng Wu, et al.

European Radiology|July 7, 2019

Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrenceJohn M Findlay, Edward Dickson, Cristina Fiorani, et al.

BMC Cancer|April 10, 2024

Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 studyElena Elez, Antonio Cubillo, Pilar Garcia Alfonso, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2024

Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 TrialsJeffrey S Weber, Mark R Middleton, Georgia Yates, et al.

Journal of Therapeutic Ultrasound|November 10, 2017

Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumoursPaul C Lyon, Lucy F Griffiths, Jenni Lee, et al.

British Journal of Cancer|May 27, 2021

Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumoursMark R Middleton, Emma Dean, Thomas R J Evans, et al.

Pageof 14

Showing results (31-40 of 136) with videos related to

Sort By:

Pageof 14

Journal for Immunotherapy of Cancer|June 8, 2019

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanomaRobert H I Andtbacka, Frances Collichio, Kevin J Harrington, et al.

British Journal of Cancer|June 2, 2025

Preferences for multi-cancer tests (MCTs) in primary care: discrete choice experiments of general practitioners and the general public in EnglandJohn Buckell, Nomalanga Madyiwa, Gail Hayward, et al.

International Journal of Cancer|February 6, 2019

Immunophenotypes of pancreatic ductal adenocarcinoma: Meta-analysis of transcriptional subtypesInes de Santiago, Christopher Yau, Lara Heij, et al.

Frontline Gastroenterology|October 29, 2019

Immunotherapy-related hepatitis: real-world experience from a tertiary centreVincent Cheung, Tarun Gupta, Miranda Payne, et al.

Ultrasound in Medicine & Biology|June 29, 2004

Contrast-enhanced ultrasound assessment of tissue response to high-intensity focused ultrasoundJames E Kennedy, Gail R ter Haar, Feng Wu, et al.

European Radiology|July 7, 2019

Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrenceJohn M Findlay, Edward Dickson, Cristina Fiorani, et al.

BMC Cancer|April 10, 2024

Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 studyElena Elez, Antonio Cubillo, Pilar Garcia Alfonso, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2024

Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 TrialsJeffrey S Weber, Mark R Middleton, Georgia Yates, et al.

Journal of Therapeutic Ultrasound|November 10, 2017

Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumoursPaul C Lyon, Lucy F Griffiths, Jenni Lee, et al.

British Journal of Cancer|May 27, 2021

Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumoursMark R Middleton, Emma Dean, Thomas R J Evans, et al.

Pageof 14